Cencora delivered solid Q1 FY2026 performance with mid-single-digit revenue growth, higher operating income, and strong adjusted EPS, driven primarily by U.S. Healthcare Solutions and the completion of the OneOncology acquisition.

Cencora ended its fiscal 2025 with solid revenue and adjusted earnings growth, though the quarter showed a GAAP net loss due to impairment charges. Both U.S. and International segments posted revenue increases.

Cencora delivered solid financial performance in Q3 2025 with higher revenue, EPS, and net income. Growth was fueled by strength in U.S. operations and benefits from recent acquisitions.

Cencora delivered robust Q2 results with $75.5B in revenue and a significant boost in earnings. The company raised its full-year adjusted EPS guidance due to continued strength in the U.S. Healthcare Solutions segment.

Cencora reported a strong start to fiscal year 2025, with revenue increasing by 12.8% year-over-year to $81.5 billion. GAAP diluted EPS was $2.50, while adjusted diluted EPS increased by 13.7% to $3.73. The company has raised its adjusted diluted EPS guidance for fiscal year 2025 to a range of $15.25 to $15.55.

Cencora's fiscal 2024 fourth quarter saw a significant revenue increase of 14.7% to $79.1 billion. GAAP diluted EPS was $0.02, while adjusted diluted EPS rose by 16.8% to $3.34. The company also announced an 8% increase in its quarterly dividend.

Cencora reported a strong third quarter in fiscal year 2024, with revenue reaching $74.2 billion, a 10.9% increase year-over-year. Adjusted diluted EPS increased by 14.4% to $3.34. The company has raised its fiscal year 2024 adjusted diluted EPS guidance to a range of $13.55 to $13.65.

Cencora reported a strong second quarter with revenue increasing by 7.8% year-over-year to $68.4 billion. GAAP diluted EPS was $2.09, while adjusted diluted EPS increased by 8.6% to $3.80. The company raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.30 to $13.50.

Cencora's first quarter fiscal year 2024 showed strong performance with a 15.0% increase in revenue to $72.3 billion. GAAP diluted EPS was $2.98, while adjusted diluted EPS increased to $3.28. The company has raised its adjusted diluted EPS guidance for fiscal year 2024 to a range of $13.25 to $13.50.

Cencora reported a 12.7% increase in revenue to $68.9 billion for Q4 2023. GAAP diluted EPS was $1.72, while adjusted diluted EPS increased by 10.0% to $2.86. The company's U.S. Healthcare Solutions and International Healthcare Solutions segments both contributed to the revenue growth.

Cencora reported a strong Q3 2023 with revenue reaching $66.9 billion, an 11.5% increase year-over-year. GAAP diluted EPS was $2.35, and adjusted diluted EPS was $2.92. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to a range of $11.85 to $11.95.

AmerisourceBergen Corporation's Q2 2023 earnings showcased a robust 9.9% increase in revenue, reaching $63.5 billion. Adjusted diluted EPS grew by 8.7% to $3.50, reflecting the company's strong financial performance and strategic execution. The company raised its full-year financial outlook, demonstrating the value of its pharmaceutical-centric strategy and key strategic partnerships.

AmerisourceBergen reported a solid first quarter with a 5.4% increase in revenue to $62.8 billion. GAAP diluted EPS was $2.33, and adjusted diluted EPS increased by 5.0% to $2.71. The company raised its adjusted diluted EPS guidance for fiscal year 2023 to $11.50 to $11.75.

AmerisourceBergen Corporation reported a 3.8% increase in revenue for the fourth quarter of fiscal year 2022, reaching $61.2 billion. GAAP diluted EPS was $1.40, while adjusted diluted EPS increased by 8.8% to $2.60. The company's performance was driven by growth in U.S. Healthcare Solutions, offset by a decrease in International Healthcare Solutions due to foreign currency translation.

AmerisourceBergen reported a strong third quarter with revenue increasing by 12.5% year-over-year to $60.1 billion. The company raised its full year outlook for adjusted diluted EPS to a range of $10.90 to $11.10.

AmerisourceBergen reported a strong second quarter with revenue increasing by 17.4% year-over-year to $57.7 billion. GAAP diluted EPS was $2.59, and adjusted diluted EPS increased by 27.3% to $3.22. The company also raised its adjusted diluted EPS guidance for fiscal year 2022 to a range of $10.80 to $11.05.

AmerisourceBergen reported a strong first quarter with revenue increasing by 13.5% year-over-year to $59.6 billion. Adjusted diluted EPS increased by 18.3% to $2.58. The company has raised its adjusted diluted EPS guidance for fiscal year 2022 to a range of $10.60 to $10.90.

AmerisourceBergen's Q4 2021 revenue increased by 19.6% to $58.9 billion. GAAP diluted EPS was $2.08, while adjusted diluted EPS increased by 26.5% to $2.39. The company's performance was driven by growth in Pharmaceutical Distribution Services and the acquisition of Alliance Healthcare.

AmerisourceBergen Corporation reported a 17.7% increase in revenue to $53.4 billion for the third quarter of fiscal year 2021. The company's GAAP diluted EPS was $1.40, while adjusted diluted EPS increased to $2.16. The company has raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $9.15 to $9.30.

AmerisourceBergen reported a solid performance in the March quarter, with revenue increasing by 3.7% year-over-year to $49.2 billion. The company's adjusted diluted EPS increased by 5.4% to $2.53, and the adjusted diluted EPS guidance for fiscal year 2021 has been raised to a range of $8.45 to $8.60.

AmerisourceBergen reported a strong first quarter in fiscal year 2021, with revenue increasing by 9.7% year-over-year to $52.5 billion. GAAP diluted EPS was $1.81, and adjusted diluted EPS increased by 24% to $2.18. The company raised its adjusted diluted EPS guidance for fiscal year 2021 to a range of $8.40 to $8.60.

AmerisourceBergen Corporation reported a 7.9% increase in revenue to $49.2 billion for the fourth quarter of fiscal year 2020. GAAP diluted EPS was $(23.74), while adjusted diluted EPS increased 17.4% to $1.89. The company recorded a $6.6 billion expense accrual related to opioid lawsuits.

AmerisourceBergen reported a slight increase in revenue for Q3 2020, with a rise in adjusted diluted EPS. The company raised its adjusted diluted EPS guidance for fiscal year 2020.

AmerisourceBergen reported a 9.5% increase in revenue to $47.4 billion for the second quarter of fiscal year 2020. GAAP diluted EPS was $4.64, while adjusted diluted EPS increased by 13.7% to $2.40. The company has revised its adjusted diluted EPS guidance for fiscal year 2020 to $7.35 to $7.65.

AmerisourceBergen reported a strong first quarter in fiscal year 2020, with revenue reaching $47.9 billion, a 5.4% increase year-over-year. Adjusted diluted EPS grew by 10.0% to $1.76. The company has raised its adjusted diluted EPS guidance range for fiscal year 2020 to $7.55 to $7.80. The Board of Directors also increased the quarterly dividend rate by 5% to $0.42 per share.